Novem Group Invests $739,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Novem Group acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,038 shares of the biopharmaceutical company's stock, valued at approximately $739,000.

Other hedge funds have also made changes to their positions in the company. Merit Financial Group LLC boosted its stake in Regeneron Pharmaceuticals by 8.9% during the 4th quarter. Merit Financial Group LLC now owns 868 shares of the biopharmaceutical company's stock worth $618,000 after purchasing an additional 71 shares during the period. Diversify Advisory Services LLC acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $234,000. Crossmark Global Holdings Inc. increased its stake in Regeneron Pharmaceuticals by 3.6% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,654 shares of the biopharmaceutical company's stock valued at $1,890,000 after purchasing an additional 92 shares during the last quarter. Aspiriant LLC grew its position in Regeneron Pharmaceuticals by 14.5% in the 4th quarter. Aspiriant LLC now owns 387 shares of the biopharmaceutical company's stock worth $276,000 after purchasing an additional 49 shares during the last quarter. Finally, Atomi Financial Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 7.0% during the fourth quarter. Atomi Financial Group Inc. now owns 615 shares of the biopharmaceutical company's stock valued at $438,000 after acquiring an additional 40 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on REGN shares. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. TD Cowen decreased their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. Finally, Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded up $17.33 during trading on Tuesday, hitting $605.67. The company had a trading volume of 285,081 shares, compared to its average volume of 799,425. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The stock has a fifty day simple moving average of $590.70 and a two-hundred day simple moving average of $672.23. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $65.39 billion, a price-to-earnings ratio of 15.81, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the firm earned $9.55 earnings per share. The company's revenue for the quarter was down 3.7% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.